Southeast Asian healthcare ventures are tapping massive overseas clinical ecosystems to overcome domestic constraints in patient trial recruitment and industrial scaling. By utilizing extensive regional hospital networks and robust local manufacturing, these firms significantly lower research expenditures while slashing therapy commercialization timelines. In particular, A*STAR spin-offs Lion TCR and BetaLife have established research, clinical, and manufacturing presences in Chinese cities to accelerate therapies for liver cancer and diabetes. Their expansion is supported by regulatory pathways like State Council Decree No. 818 and direct guidance from Enterprise Singapore.
Key points
Expanding into China provides biomedical firms with access to expansive patient populatio…: Expanding into China provides biomedical firms with access to expansive patient populations and integrated clinical infrastructure.
Substantial cost savings and compressed trial timelines drive biotechnology startups to r…: Substantial cost savings and compressed trial timelines drive biotechnology startups to relocate parts of their clinical pipelines abroad.
Government initiatives and regulatory reforms such as Decree No. 818 help foreign healthc…: Government initiatives and regulatory reforms such as Decree No. 818 help foreign healthcare enterprises navigate complex local approval processes.
Sources checked by our analysis pipeline: 1
Singapore startups are tapping China’s vast patient pool, hospital networks and manufacturing capabilities, but they must also navigate its evolving regulatory landscape.
GUANGZHOU: At a laboratory in Guangzhou, scientists are developing a new way to treat liver cancer by reprogramming the body’s own immune cells to recognise and attack tumours.
The method, developed by Singapore biotechnology firm Lion TCR, targets liver cancer linked to hepatitis B, a disease prevalent in China and parts of Asia.
The company is among Singapore biomedical startups tapping China’s vast patient pool, hospital networks and manufacturing capabilities to accelerate development of new therapies.
SPEEDING UP CANCER TREATMENT DEVELOPMENT
A spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR), Lion TCR conducted its first clinical trials at Singapore General Hospital before expanding to China.
The company has since established a facility at the China-Singapore Guangzhou Knowledge City where it is leveraging an integrated research-to-manufacturing ecosystem to cut down on development time by roughly half.
“Lion TCR actually shortened the distance between innovation, clinical needs and the manufacturers,” said the company’s CEO Peng Xiaoming.
Acting on intelligence regarding a planned major incident, a joint operation by the Patna Special Task Force and local police intercepted suspects with existing criminal records in Sherpur. The suspects initiated heavy gunfire, sparking an armed confrontation that left an officer wounded and all three targets fatally injured. Authorities managed to neutralize individuals wanted across multiple jurisdictions while seizing several firearms and ammunition from the scene.
The long-term casualties of the Hanukkah festival shooting continue to mount as an elderly victim succumbed to complications stemming from her bullet wounds. The tragedy has renewed attention on the mass casualty event that devastated the local Jewish community and prompted sweeping terrorism charges. Her passing comes as legal proceedings against the surviving gunman move forward.
Federal regulators have granted marketing authorization for Johnson & Johnson's oncology drug, Rybrevant. The decision expands therapeutic choices for patients facing specific forms of cancer. Healthcare providers now have clearance to incorporate this pharmaceutical option into relevant treatment plans.